McKesson Corp (MCK)

A. Company Overview

McKesson Corporation is a prominent player in the healthcare sector, tracing its roots back to 1833. The company has evolved into a diversified healthcare services leader focused on enhancing health outcomes for patients globally. It collaborates with a diverse array of stakeholders, including biopharmaceutical companies, healthcare providers, pharmacies, manufacturers, and governments. McKesson provides insights, products, and services designed to make quality care more accessible and affordable. The company operates under a fiscal year that commences on April 1 and concludes on March 31 of the following year. The incorporation of McKesson Corporation occurred on July 7, 1994, in the State of Delaware.

B. Business Segments

McKesson's operations are categorized into four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.

U.S. Pharmaceutical Segment

The U.S. Pharmaceutical segment is instrumental in distributing a comprehensive range of pharmaceutical drugs within the United States, encompassing branded, generic, specialty, biosimilar, and over-the-counter (OTC) products. In addition to drug distribution, this segment provides value-added services such as practice management, technology support, clinical assistance, and business solutions tailored to community-based oncology and specialty practices. It also serves a variety of customers, including hospitals, pharmacies (retail, hospital, and alternate sites), pharmaceutical manufacturers, and payers.

This segment operates through a network of 27 distribution centers across the U.S., equipped with advanced technological systems to bolster safety, reliability, and product availability. The implementation of McKesson Connect™, an internet-based ordering platform, enhances customer experience by offering real-time inventory checks and streamlining ordering processes.

Key distribution channels include retail national accounts, community pharmacies, institutional healthcare providers, and specialty partners. Enhancing customer revenue and profitability is paramount, achieved through services like Central Fill™ — enabling pharmacies to refill prescriptions efficiently and accurately.

Prescription Technology Solutions Segment

The Prescription Technology Solutions segment addresses challenges related to medication access, affordability, and adherence. This segment effectively connects various stakeholders across the healthcare system, facilitating medication access from the initial prescription fill to ongoing therapy. Its solutions encompass prescription price transparency, benefit insights, dispensing support, and third-party logistics.

Through established partnerships with biopharma entities and other healthcare stakeholders, RxTS has facilitated significant cost savings for patients, while proactively preventing prescription abandonment, thereby improving overall health outcomes.

Medical-Surgical Solutions Segment

This segment caters to a vast customer base of over 285,000, including physician offices, surgery centers, nursing homes, and home healthcare agencies. It provides a broad array of medical-surgical supplies, pharmaceuticals, and logistics services through a nationwide distribution network in the U.S. With more than 245,000 products, including both branded and McKesson’s proprietary offerings, this segment plays a crucial role in enhancing operational efficiency and compliance among healthcare providers. Services offered also include inventory management and administrative support aimed at improving patient care.

International Segment

McKesson's International segment extends its distribution and services to wholesale, institutional, and retail customers in Canada and Europe. In Canada, McKesson is a leading pharmaceutical distributor, providing critical services to various healthcare entities, including hospital systems and long-term care centers. Its operations accommodate retail health brands and several specialty health services designed to optimize patient care experiences.

Following strategic decisions in July 2021 to exit European businesses, McKesson divested significant portions of its operations within that region while retaining a presence in Norway to service local customers.

C. Investments, Restructuring, Business Combinations, and Divestitures

McKesson actively invests in enhancing its infrastructure with distribution centers to boost scale and improve operational efficiencies through automation. Strategic initiatives focused on enhancing core healthcare services have been prioritized to solidify McKesson’s competitive standing in the market. Exploration of artificial intelligence (AI) capabilities is also underway to improve productivity and inform decision-making across departments.

D. Competition

McKesson operates in a competitive landscape characterized by intensified consolidation within the healthcare sector. In the pharmaceutical distribution domain, key competitors include well-established companies such as Cencora, Inc. and Cardinal Health, Inc. The competitive environment extends across distribution channels servicing pharmacies and healthcare providers, where market incumbents vie for market share based on criteria such as pricing, quality of services, and breadth of product offerings.

E. Patents, Trademarks, Copyrights, and Licenses

McKesson maintains an extensive portfolio of patents, trademarks, and copyrights pertinent to its various products and services. This portfolio safeguards the company's innovations and proprietary technologies. While McKesson views its intellectual property as a strategic advantage in the competitive marketplace, it also recognizes the inherent risks associated with potential infringements and disputes surrounding its intellectual property.

F. Other Information about the Business

Sales distribution is highly concentrated, with a significant percentage stemming from a limited number of customers, including notable partners like CVS Health Corporation. McKesson also maintains strategic relationships with suppliers, enabling it to secure essential pharmaceuticals and healthcare-related products. The company invests in research and development, reflecting its commitment to innovation in healthcare services.